The Pink Journal
The Pink Journal
Audio Summaries
American journal of obstetrics & gynecology MFM
Every issue of The Pink Journal moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from The Pink Journal.
Examining the intersection of extreme heat exposures, social determinants of health, and adverse pregnancy outcomes: a scoping review.
Nov 20, 2026
This scoping review of 37 U.S. studies asks how extreme heat during pregnancy relates to adverse pregnancy outcomes (such as preterm birth, stillbirth, and gestational diabetes) and how social determinants of health, especially area-level measures like neighborhood deprivation and greenness, are defined and incorporated in this literature. The authors found that heat exposure was consistently linked to multiple adverse outcomes, with five of twelve studies reporting stronger associations in disadvantaged or low-greenness areas, though area-level measures appeared in fewer than half of the empirical studies. They conclude that standardized use of place-based measures is needed to better identify communities most vulnerable to heat-related pregnancy harms.
First trimester cervical length and cervical change in the prediction of prematurity related outcomes.
Nov 19, 2026
This retrospective study of 6,116 singleton pregnancies asked whether first-trimester cervical length (CL), and the change in CL between the first and second trimesters, predict prematurity-related outcomes such as late miscarriage, cervical shortening, cerclage placement, and spontaneous preterm delivery. Shorter first-trimester CL was significantly associated with these outcomes, with risk rising nonlinearly below 30 mm (about a 26% increase in combined adverse outcome risk per 1 mm decrease). Pregnancies with adverse outcomes also showed a steeper cervical shortening between trimesters (-9.4% vs -0.03%), and combining second-trimester CL with the change in CL improved prediction over single measurements.
AI feedback for clinician assessment of umbilical and middle cerebral artery Doppler ultrasound: a multicenter randomized trial.
Nov 6, 2026
This multicenter randomized trial tested whether AI-generated visual and textual feedback improves clinicians' accuracy in assessing standardized umbilical artery and middle cerebral artery Doppler ultrasound images, using 96 clinicians across five Danish hospitals. AI feedback raised overall accuracy from 62.3% to 75.0%, with significant gains for both novice and experienced clinicians. Novices were more likely than experienced clinicians to follow incorrect AI advice, highlighting the continued importance of clinical experience.
Ophthalmic Artery versus Uterine Artery Doppler in the prediction of preterm pre-eclampsia at 11-13 weeks' gestation.
Nov 4, 2026
This prospective study of 946 women undergoing first-trimester screening asked whether maternal ophthalmic artery Doppler (Oph-PR) can match uterine artery Doppler (UtPI) for predicting preterm pre-eclampsia when added to maternal factors, mean arterial pressure, and PlGF. The two Doppler approaches performed comparably (AUCs of 0.805 to 0.837 for UtPI versus 0.789 to 0.830 for Oph-PR, with no significant difference), and combining both indices gave the highest accuracy (AUC 0.919). The authors conclude that Oph-PR is a viable alternative to UtPI, and that using both may improve preterm pre-eclampsia prediction, though only 21 women had preterm pre-eclampsia, which limits the strength of these findings.
First- and second-generation antipsychotic use in pregnancy and risks of pregnancy and birth outcomes.
Nov 4, 2026
This Danish population-based cohort study (2004-2022) asked whether continuing first- or second-generation antipsychotics during pregnancy is linked to gestational diabetes, gestational hypertension, and adverse birth outcomes compared with discontinuing them. Among 7,417 pregnancies, continuing second-generation antipsychotics was associated with non-significant trends toward higher gestational diabetes and hypertension (with the hypertension signal limited to high-metabolic-risk agents) and with lower odds of preterm birth, while first-generation continuation was linked to higher neonatal intensive care admission but not to maternal risk. The authors conclude that second-generation continuation carries maternal metabolic risk, whereas first-generation continuation is associated mainly with neonatal intensive care admission.
Tranexamic Acid Prophylaxis During Cesarean Delivery Among Patients with and Without Hypertension.
Nov 4, 2026
This secondary analysis of the multicenter, placebo-controlled TXA trial asked whether prophylactic tranexamic acid during cesarean delivery works differently in patients with chronic or pregnancy-related hypertension than in those without. Among 10,995 participants (24.6% with hypertension), TXA's effect on the composite of transfusion or maternal death within 7 days was similar across groups (RR 0.84 with hypertension vs. 0.91 without; interaction p = 0.64), as were all secondary bleeding outcomes. The authors conclude that TXA's benefit does not depend on hypertensive status, supporting its use regardless of hypertension, though this was a non-prespecified analysis.
Outcomes in Stage II twin-twin transfusion syndrome with donor intermittent umbilical artery Doppler abnormalities.
Nov 4, 2026
This study compared laser surgery outcomes in monochorionic twin pregnancies with stage II TTTS, divided by whether donor umbilical artery Doppler showed intermittent absent/reversed end-diastolic flow or a normal waveform, with stage III (persistent UA-AREDF) as a comparison group. The authors asked whether intermittent UA-AREDF in stage II carries higher donor fetal demise risk, finding donor IUFD rates of 8.1% vs 7.1% (normal) vs 29.2% (stage III), and no significant increase in adjusted risk for intermittent cases (aOR 0.51, 95% CI 0.15–1.79). These findings support the original Quintero staging, which reserves stage III for persistent donor UA-AREDF only.
Personalized machine learning model for predicting successful vaginal delivery during the active phase of labor.
Nov 3, 2026
This study asks whether a personalized, explainable machine learning model can predict successful vaginal delivery in real time during the active phase of labor using both static maternal characteristics and dynamic intrapartum data. Using 70,000 active-phase labor records from a tertiary hospital (2010-2021), the authors found that a Histogram-Based Gradient Boosting model performed best (ROC AUC 0.87, PR AUC 0.52), with fetal descent rate, cervical opening rate, maternal age, and clinical fetal weight estimate contributing most to predictions, as revealed by SHAP analysis.
HypoxIA: A bicenter study of machine learning-based prediction of fetal hypoxia using fetal heart rate and obstetric features.
Nov 3, 2026
This bicenter study of 3,574 singleton deliveries asked whether a machine learning model combining intrapartum cardiotocography (CTG) signals with routine clinical data could predict neonatal acidemia (umbilical arterial pH <7.15) and severe acidemia (pH <7.05). The model performed best for severe acidemia (AUC 0.78 in the final hour before birth) and, at the same false-positive rate as clinical practice, achieved higher sensitivity than clinical intervention for severe acidemia. Explainability analysis showed that CTG-derived features drove predictions while clinical variables added little, suggesting explainable AI may support CTG interpretation during labor.
Offering prenatal CFTR modulators to prevent cystic fibrosis-related organ damage in utero.
Nov 3, 2026
This case series from one center describes eight pregnancies at risk for cystic fibrosis in which prenatal CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor) was offered, with only two women ultimately receiving it. In both treated cases, fetal bowel obstruction findings improved or resolved and the infants were born without meconium ileus, though the small sample and lack of a control group limit any conclusions about efficacy. The authors conclude that decisions about prenatal modulator therapy are complicated by variable genotype-phenotype relationships, inconsistent insurance coverage, and uncertain risks and benefits.
